London Regenerative Medicine Network, 14a Clerkenwell Green, London EC1R 0DP, UK.
Regen Med. 2012 Nov;7(6 Suppl):136-8. doi: 10.2217/rme.12.73.
2012 has been an exciting year in the UK with substantial development on every front - research, clinical, industry and government. In particular, the focus has now moved to encompass far more post-research activities, with the continued enrolment of patients onto two pioneering Phase I clinical trials: ReNeuron's ReN001 stem cell therapy for stroke (PISCES) in Southern General Hospital, Greater Glasgow and Advanced Cell Technology's retinal pigment epithelial cells derived from human embryonic stem cells for Stargardts macular dystrophy and dry age-related macular degeneration at Moorfields Eye Hospital, London. The funding landscape for the sector has evolved from previous years to more fully embrace development and translation, including the provision of £180 million available for biomedical research via the Biomedical Catalyst Fund (joint Technology Strategy Board and Medical Research Council [MRC] funding) and a further £25 million through the UK Research Council's UK Regenerative Medicine Platform initiative, as well as ongoing developments with the Cell Therapy Catapult, which all act to further encourage a pan-UK collaborative environment. Overall, the UK cell therapy community continues to thrive and impact heavily upon the worldwide sector, with an established research base, a solid approach to translation and a small but growing commercial sector that is going from strength to strength.
2012 年是英国令人兴奋的一年，在各个方面都取得了实质性的发展——研究、临床、工业和政府。特别是，现在的重点已经转移到包含更多的研究后活动，继续招募患者参加两项开创性的 I 期临床试验：雷纽隆的用于中风的 ReN001 干细胞疗法（南方综合医院，格拉斯哥大）和先进细胞技术公司的源自人类胚胎干细胞的视网膜色素上皮细胞用于斯特格氏黄斑营养不良和干性年龄相关性黄斑变性（伦敦莫菲尔兹眼科医院）。该领域的资金环境已经从过去几年发展到更全面地涵盖开发和转化，包括通过生物医学催化剂基金（联合技术战略委员会和医学研究理事会[MRC]资助）提供 1.8 亿英镑用于生物医学研究，以及通过英国研究理事会的英国再生医学平台计划提供另外 2500 万英镑，以及细胞治疗弹射器的持续发展，所有这些都进一步鼓励了全英合作环境。总的来说，英国细胞治疗界继续蓬勃发展，并对全球领域产生了重大影响，拥有成熟的研究基础、扎实的转化方法和一个规模虽小但不断壮大的商业领域。
